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Background: Newcastle Disease Virus (NDV) causes a serious infectious disease in birds that results in severe losses
in the worldwide poultry industry. Despite vaccination, NDV outbreaks have increased the necessity of alternative
prevention and control measures. Several recent studies focused on antiviral compounds obtained from natural
resources. Many extracts from marine organisms have been isolated and tested for pharmacological purposes, and
their antiviral activity has been demonstrated in vitro and in vivo. Fucoidan is a sulfated polysaccharide present in
the cell wall matrix of brown algae that has been demonstrated to inhibit certain enveloped viruses with low
toxicity. This study evaluated the potential antiviral activity and the mechanism of action of fucoidan from
Cladosiphon okamuranus against NDV in the Vero cell line.
Methods: The cytotoxicity of fucoidan was determined by the MTT assay. To study its antiviral activity, fusion and
plaque-forming unit (PFU) inhibition assays were conducted. The mechanism of action was determined by time of
addition, fusion inhibition, and penetration assays. The NDV vaccine strain (La Sota) was used in the fusion
inhibition assays. PFU and Western blot experiments were performed using a wild-type lentogenic NDV strain.
Results: Fucoidan exhibited antiviral activity against NDV La Sota, with an obtained IS50 >2000. In time of addition
studies, we observed viral inhibition in the early stages of infection (0–60 min post-infection). The inhibition of viral
penetration experiments with a wild-type NDV strain supported this result, as these experiments demonstrated a
48% decrease in viral infection as well as reduced HN protein expression. Ribavirin, which was used as an antiviral
control, exhibited lower antiviral activity than fucoidan and high toxicity at active doses. In the fusion assays, the
number of syncytia was significantly reduced (70% inhibition) when fucoidan was added before cleavage of the
fusion protein, perhaps indicating a specific interaction between fucoidan and the F0 protein.
Conclusion: The results of this study suggest that fucoidan from C. okamuranus represents a potential low-toxicity
antiviral compound for the poultry industry, and our findings provide a better understanding of the mode of action
of sulfated polysaccharides.
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Figure 1 Antiviral activity of fucoidan against NDV (syncytia
reduction). Vero cells (1.5 × 105 cells) plated in 24-well plates were
infected with NDV and treated with different concentrations of
fucoidan or ribavirin during and after infection for 48 h, and their
antiviral activity was determined in a syncytia reduction assay. The
data are expressed as relative syncytia formation (%) to that for the
untreated virus-infected control cells, which was defined as 100%.
VC, viral control. The data shown are the mean ± standard deviation
(SD) from three replicated experiments.
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In the poultry industry, viral infection causes serious
losses in productivity with important economic conse-
quences. Antiviral agents are not used because of the high
toxicity and elevated production costs associated with the
use of most antiviral compounds [1]. Exploring antiviral
substances as novel drug candidates is important because
of the increasing risks of emerging and reemerging viral
infectious diseases. Marine algae contain several metabo-
lites with biological activity that are recognized as promis-
ing antiviral agents [2]. The antiviral activity of marine
algae polysaccharides against mumps and influenza was
reported more than 50 years ago [3].
Fucoidan is a sulfated polysaccharide obtained from
marine brown algae that possesses many biological activ-
ities including activity against different viruses, such as
HIV, herpes simplex virus, dengue virus, and cytomegalo-
virus [4,5], and exerts significant biological effects on
mammalian cells [6]. Its antiviral activity appears to inhibit
the initial steps of infection [7]. Cladosiphon okamuranus
is an edible brown algae that is commercially cultured
around Okinawa Island, Japan. Fucoidan is prepared on
an industrial scale from algae and used as an additive for
health foods, drinks, and cosmetics in Japan. The chem-
ical structure of fucoidan extracted from the brown alga
Cladosiphon okamuranus was described by Nagaoka
et al. According to their findings, fucoidan possesses α
1-3–linked L-fucosyl residues that are substituted with
D-glucuronic acid at C-2 and sulfate groups at C-4 of
the l-fucosyl residues. The average branched chain struc-
ture consists of one sulfate group for every two molecules
of fucose and one glucuronic residue for every six mole-
cules of fucose [8]. The polysaccharide also contains xy-
lose as a minor monosaccharide constituent. Using a
room temperature extraction, Tako et al. reported an
acetylfucoidan yield of 2.3% (w/w) based on the wet alga
weight. The total contents of carbohydrates, D-glucur-
onic acid, sulfuric acid, ash, and moisture were 69, 13.5,
13.6, 23, and 3.2%, respectively, and the molar ratio of
L-fucose:D-xylose:D-glucuronic acid:acetic acid:sulfuric
acid was estimated to be 4.0:0.03:1.0:2.0:2.0 [9].
Newcastle Disease Virus (NDV) is an enveloped virus
that causes severe problems in the poultry industry. It is
member of the Paramyxoviridae family, and at least two
membrane glycoproteins are responsible for viral entry:
the fusion protein (F) and an attachment protein (HN,
H, or G, depending on the genus) [10,11]. For NDV, the
HN and F proteins are responsible for cell binding and
fusion, respectively. The F protein is responsible for fu-
sion of the viral envelope and cell membrane through
conformational changes [12]. The F protein is synthe-
sized initially as a precursor, F0, and then cleaved into
subunits F1 and F2 by a furin-like enzyme present in the
host cell [13]. This cleavage of the F protein is necessaryfor fusion activation [14]. Cleavage of the F0 protein is a
determinant of the pathogenicity and infectivity of NDV
[13]. In avirulent NDV strains, the F protein cannot be
cleaved by the furin-like enzyme, and it exists as F0. As
a result, the fusion process cannot be completed until an
exogenous protease such as trypsin is added to facilitate
F0 cleavage into an activated form [10]. In our study, we
evaluated the anti-NDV activity and mechanism of ac-
tion of fucoidan from Cladosiphon okamuranus.
Results
Cytotoxicity of fucoidan and ribavirin
To determine the cytotoxicity of these compounds, we
performed MTT assays. No significant cytotoxicity was
detected for fucoidan at concentrations up to 100 μg/mL
in Vero cells, and a 50% cytotoxic concentration (CC50)
> 1500 μg/mL was obtained. By contrast, ribavirin exhib-
ited sizeable cell cytotoxicity, with a CC50 of 386 μg/mL.
The antiviral assays were performed at concentrations
below or equal to 100 μg/mL for fucoidan and below or
equal to 500 μg/mL for ribavirin.
Antiviral activity in vitro
The antiviral activity of fucoidan against NDV was eval-
uated by syncytia reduction and plaque-forming unit
(PFU) inhibition assays. Vero cell monolayers were trea-
ted with different concentrations of fucoidan at the time
of infection with 800 TCID50 or 100 PFUs of NDV, and
the concentration of fucoidan was maintained through-
out the infection. As shown in Figures 1 and 2, a
concentration-dependent inhibition of viral entry into
the host cells was observed with the addition of fucoi-
dan compared to the findings in the untreated control
Figure 2 Antiviral activity of fucoidan against NDV (PFU
reduction). Vero cells (1.5 × 105 cells) plated in 24-well plates were
infected with NDV and treated with different concentrations of
fucoidan or ribavirin during and after infection for 48 h, and the
antiviral activity was determined in a PFU reduction assay. The data
are expressed as relative PFU (%) to that for the untreated
virus-infected control cells, which was defined as 100%. VC, viral
control. The data shown are the mean ± SD from four
replicated experiments.
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cytia and PFU formation in NDV, with 50% inhibitory
concentration (IC50) values of 0.75±1.6 μg/mL in the
syncytia reduction assay and 58±2 μg/mL in the PFU
inhibition assay (mean estimate ± standard error). The
selectivity index (SI50) of the compound was calculated
to be >25.8 for the inhibition of PFU, although the com-
pound displayed a much greater ability to inhibit syn-
cytia formation with a calculated SI50 of >2000. We
used ribavirin as an antiviral control and obtained IC50
values of 224±2 and 490±2 μg/mL in the syncytia reduc-
tion and PFU inhibition assays, respectively (SI50=0.78
by UFP; Figures 1 and 2).Figure 3 Time of addition experiments. Vero cells (3 × 105 cells) plated
different times of infection, and analyzed by PFU inhibition assays and imm
preinfection and 0, 15, 30, 60, and 120 min postinfection. The data are exp
control cells (VC), which was defined as 100%. The data shown are the me
difference between the treatment and viral control (*p<0.05). B) Fucoidan
with NDV, stained with a mouse monoclonal anti-NDV HN antibody, and aEffect of fucoidan on viral infection as determined by
time of addition assays
To determine which step of the NDV cycle was targeted
by fucoidan, “time of addition” experiments were per-
formed in Vero cells infected with NDV and exposed to
fucoidan at different times of infection. As shown in
Figure 3 A, the most efficient inhibition was observed in
early phases of infection (0, 15, and 30 min after infec-
tion). Fucoidan does not exhibit significant antiviral
activity before infection or 1 h after infection. We also
confirmed this result in immunofluorescence assays in-
dicating significant inhibition when the compound was
added at 0 and 15 min after infection and a weak effect
when the compound was added 1 h before or after in-
fection (Figure 3B).
According to the results obtained in the time of
addition experiments, the greatest antiviral activity was
exhibited before the first hour of infection; however, the
compound had no effect when it was added before infec-
tion, suggesting that fucoidan inhibits viral penetration
into host cells.Virucidal activity of fucoidan
To analyze the possibility that this polysaccharide acts
directly on the virus particle leading to infectivity inacti-
vation, a virucidal assay against NDV virions was con-
ducted. The virucidal effect of fucoidan against NDV
virions was negligible at the maximum tested con-
centration of 100 μg/mL. This concentration is much
higher than the antiviral EC50, indicating that the inhibi-
tory effect detected by the plaque reduction assay was
actually due to interference with some step of the NDV
replication cycle.in 6-well plates were infected with NDV, treated with fucoidan at
unofluorescence assays. A) Fucoidan was added at 60 min
ressed as relative PFU (%) compared to that of untreated virus-infected
an ± SD of triplicate experiments. The asterisks indicate a significant
was added at 60 min preinfection and 0, 15, and 60 min postinfection
nalyzed by indirect immunofluorescence as detailed in the Methods.
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To determine whether entry events downstream of virus
binding were inhibited by fucoidan, Vero cells were
incubated with NDV at 4°C for 1 h to allow virus bind-
ing but prevent viral internalization. Unbound virus was
washed away, prewarmed medium containing 0, 10, or
100 μg/mL fucoidan was added to the cells, and the
cells were then shifted to 37°C for the remainder of
the experiment. In these experiments, 10 μg/mL fucoi-
dan significantly decreased viral infection by 23% and
100 μg/mL fucoidan significantly decreased viral infec-
tion by 48% compared with the findings in infected cells
in the absence of treatment (Figure 4). These findings
supported the possibility that postbinding events are
inhibited by fucoidan.Effect of fucoidan on NDV protein synthesis
Considering the results, we decided to evaluate the effect
of fucoidan by measuring the relative concentrations of
viral protein synthesized in the cells exposed to the com-
pound at various stages of infection. When fucoidan was
added to the Vero cell monolayers at the time of viral in-
fection, HN protein levels were decreased by 64%; how-
ever, when the compound was added 15 or 30 min after
infection, HN protein levels were dramatically decreased
by 98.6 and 98.2%, respectively. The compound had a
lower effect when added 60 min after infection
(Figure 5).
These results are consistent with those observed in
trials of PFU and support the possibility that postbinding
events are likely responsible for the inhibition of NDV
infectivity by fucoidan.Figure 4 Effect of fucoidan on viral penetration. Vero cells
monolayers were infected with NDV at 4°C in the absence of
fucoidan and then shifted to 37°C to permit penetration of the
adsorbed virus in the presence of fucoidan. The effects of fucoidan
were evaluated using a PFU inhibition assay. The data shown are the
mean ± SD of triplicate experiments. The asterisks indicate a
significant difference between the treatment and viral control
(*p<0.05).Ability of fucoidan to block NDV-induced cell-cell fusion
To determine whether the compound inhibits the cell-
cell spread of NDV, we performed cell fusion inhibition
assays as described in the Methods. Avirulent strains of
NDV are characterized by their inability to form syn-
cytia because the F protein cannot be cleaved. However,
after trypsin digestion, syncytia formation is observed.
The results indicated that fucoidan inhibited syncytia
formation only if it was added before F protein cleavage
(before trypsin digestion; Figure 6A). Before F protein
cleavage, fucoidan inhibited syncytia formation by 70%
and decreased the number of syncytial nuclei by 64.8%
compared with the findings in untreated viral-infected
control cells. However, after F protein cleavage via tryp-
sin digestion, fucoidan lost the ability to inhibit syncytia
formation (Figure 6B). This suggests that fucoidan inhi-
bits viral fusion by interacting with the intact F0 protein
but not with the mature F protein (i.e., the activated
form of the F1/F2 complex).
Discussion
Newcastle disease (ND) is one of the most serious infec-
tious diseases affecting birds, particularly poultry, and it
has been the cause of serious economic losses [1]. There
is no treatment for ND. Vaccination is practiced widely,
and it remains the recommended method for prevention.
Although vaccination using live and killed vaccines is
widely used as a management practice, the velogenic
strains are endemic in the commercial poultry of many
countries [15,16]. This represents a major problem for
the poultry industry and therefore requires further mea-
sures to prevent and control this disease.
Antiviral treatments are not available in poultry due to
their cost and toxicity, and thus, a promising alternative
is the use of compounds of natural origin, which have
been underexplored for this purpose [17,18]. Several sul-
fated seaweed polysaccharides have been demonstrated
to exhibit antiviral activity against a wide spectrum of
viruses [4,5,7,19] with effectiveness that depends on the
sugar composition, main chain length, sulfation level,
and sulfate pattern [20,21]. An advantage of sulfated
polysaccharides from algae is the high content of polya-
nions in their extracellular matrix; consequently, they
can be prepared and made available at a very low cost,
and sulfated polysaccharides isolated from many marine
algae possess species-specific structural variations that
appear to affect their antiviral activity [22].
The major undesirable side effect of sulfated polysac-
charides is their well-known anticoagulant activity. This
adverse effect can be avoided by selecting sulfated poly-
mers, such as fucoidan from C. okamuranus, which ex-
hibit virtually no anticoagulant activity [23]. Cumashi
et al. suggested that the high presence of glucuronic acid
branches is the most likely feature responsible for the
Figure 5 NDV HN protein levels in Vero cells infected with NDV and treated with fucoidan. Vero cells (3 × 105) were infected with NDV
and treated with 100 μg/mL fucoidan at different times of infection. Lane 1, cellular control without NDV infection (CC); Lane 2, viral control
without fucoidan treatment (VC), Lanes 3–7, cells infected with NDV and treated with fucoidan at 60 min before and 0, 15, 30, and 60 min after
infection, respectively. Cells lysates were prepared, and equal amounts of protein extracts (40 μg) were subjected to immunoblot analysis to
detect HN and GAPDH levels. The ratio of HN/GAPDH expression in the immunoblot analysis was quantified using Phoretix1D v2003.02 software.
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dan, as the less active compounds are characterized by a
low degree of sulfation and a high presence of 2-O-α-D-
glucuronyl substituents along the linear polysaccharide
backbone (Characteristics fucoidan from C. okamura-
nus) [23]. By contrast, it has been proposed that the
antiviral activity of fucoidan is related to the concentra-
tion of fucose and uronic acids. Hidari et al. found that
the antiviral properties of fucoidan from C. okamuranus
against dengue virus type 2 vanished when the glucur-
onic acid was carboxyl-reduced [5], and Jiao et al. indi-
cated that a carboxyl-reduced fucoidan derivative from
C. okamuranus, which contained fucose and sulfate
groups but no uronic acids, did not display significant
antiviral effects against influenza A [21]. In the present
study, we evaluated the antiviral activity of fucoidanFigure 6 Inhibition of avirulent NDV (La Sota) strain-mediated cell fus
a) Uninfected control cells; b) Vero cells infected with NDV and treated wit
protein cleavage, at which point syncytia formation could be inhibited if fu
after F protein cleavage, and fucoidan could not inhibit syncytia formation
before (BC) and after F protein cleavage (AC). Data are expressed as percen
findings in untreated virus-infected control cells. VC, viral control. The data
indicate a significant difference between the treatment and viral control (*from C. okamuranus extracted by the method of Tako
et al. with a significant degree of uronic acids, and
investigated its possible mechanism of action in Vero
cells [9].
There are very few drugs available for the treatment of
infections caused by RNA viruses. Ribavirin inhibits
many paramyxoviruses in vitro, such as parainfluenza,
the measles virus, the mumps virus, RSV, and canine
distemper virus [24,25]. Ribavirin is approved for the
treatment of RSV infection in children; however, the
efficacy of ribavirin against RSV is limited [26]. In our
work, ribavirin did not display good antiviral activity be-
cause its IC50 was 490, and its CC50 was close to that
value (SI50=0.78). Conversely, according the findings, no
significant in vitro toxicity was observed with fucoidan,
as its CC50 was >1500 μg/mL. Previous studies reportedion. A) Vero cells infected with NDV and treated by trypsin digestion:
h trypsin; c) Infected Vero cells were treated with fucoidan before F
coidan was added; d) Infected Vero cells were treated with fucoidan
in this condition. B) Fusion inhibition assay with fucoidan treatment
t of the number of syncytia and syncytial nuclei compared with the
shown are the mean ± SD of triplicate experiments. The asterisks
p<0.05).
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from different algal sources, consistent with our findings
for fucoidan [27]. Additionally, in the study by Gideon
and Rengasamy, rats treated with C. okamuranus exhib-
ited no necropsy or other pathological changes in organs
or changes in histopathological morphology, consistent
with the lower toxicity possessed by sulfated polysac-
charides, specifically fucoidan from C. okamuranus [28].
Fucoidan from C. Okamuranus exhibited good antiviral
activity against NDV, with an SI50 of >25.8, although the
compound displayed a much greater ability to inhibit syn-
cytia formation, with a calculated SI50 of >2000. Therefore,
fucoidan from C. okamuranus much more effectively
inhibited NDV. Similar results were obtained for other
sulfated polysaccharides from different algae against sev-
eral enveloped viruses [5,19,26,29]; however; it appears
clear that specific interactions between viruses and sul-
fated polysaccharides are related to the particular charac-
teristics of the viruses and compounds. Variations in the
amino acid sequence of the viral envelope glycoproteins
result in differential susceptibilities to the compounds that
interact with them [30-33]. Studies of structures related
with the antiviral effect of Cladosiphon fucoidan against
dengue viruses strongly suggested that both glucuronic
acid and sulfated fucose residues in fucoidan appear to
critically affect its antiviral effect [5]. Fucoidan from
C. okamuranus exhibited significant antiviral activity
against NDV infection in this study, therefore suggesting a
specific inhibition of NDV infection in host cells.
We found a virucidal effect negligible of fucoidan
against NDV virions, indicating that the inhibitory effects
detected by the inhibition syncytia or plaque reduction
assays were actually due to interference with some step of
the NDV replication cycle. The lack of virucidal activity
for fucoidan from C. okamuranus is in accordance with
previous studies that found most algal sulfated polysacchar-
ides cannot induce significant virion inactivation [34-36].
According our results obtained by time of addition
assays, fucoidan exerted an inhibitory effect on the early
phases of the virus-cell interaction (Figure 3). These
results agree with previously reported data indicating
that algae-derived sulfated polysaccharides can inhibit
viral infection by interfering with the binding and pene-
tration of the virus into cells [5,37]. We further con-
firmed the antiviral activity by Western blotting using
NDV-infected Vero cells that were treated with fucoidan
at different times after infection. Our results clearly re-
veal marked inhibition of HN protein expression, with
the greatest inhibition obtained at 15 min post-infection
(Figure 5). These results support the ability of fucoidan
to block the early stages of infection.
As judged by our findings, fucoidan acts in early steps
of infection and inhibits syncytia formation. Therefore,
we decided to determine the specific viral step(s) inhibitedby fucoidan. The NDV envelope contains two proteins
related to entry: the attachment protein HN and the fu-
sion protein F. Fusion of the viral envelope with the cell
membrane occurs after attachment via conformational
changes in the F protein that are specifically arrested at
4°C. The addition of fucoidan after prebinding of NDV to
cells effectively blocked viral infection (Figure 4). These
findings suggest that fucoidan principally inhibits NDV
infectivity by blocking one or more postbinding entry
steps.
As described in this study, although the primary anti-
viral targets of fucoidan were suggested to be early
stages of NDV infection, fucoidan inhibited the cell-to-
cell spread of NDV when added to the medium at 12 h
postinfection. Regarding avirulent NDV strains, fusion
did not occur without the addition of trypsin in the fu-
sion inhibition assays with NDV La Sota, and we only
observed antiviral activity when fucoidan was added be-
fore F protein cleavage, indicating that the compound
inhibits fusion, perhaps via a direct effect on the F0 pro-
tein (Figure 6). As a consequence of this mode of action,
fucoidan both inhibits the penetration of NDV to cells
and strongly suppresses NDV-induced syncytia forma-
tion between NDV-infected cells and uninfected cells, a
process that drastically enhances NDV spread and in-
fectivity. Our results agree with those of Parskaleva
et al., who demonstrated the ability of an extract from
Sargassum fusiforme to inhibit the entry events of HIV
and the mechanism by which HIV infection spreads [38].
In the penetration inhibition assays, we observed a re-
duction in viral infection when fucoidan was added after
adsorption. As the cellular receptor to which the virus
binds is already known (Figure 4), this finding suggests
that the inhibitory effect of fucoidan on the viral F pro-
tein may be principally responsible for this inhibition
and not an effect on the cellular receptor (when the F
protein is possibly exposed to the compounds). However,
we cannot rule out an effect on the HN protein, as the
fusion mediated by the NDV F protein absolutely requires
the participation of the HN protein [12]. Our findings sug-
gest that the inhibition of virus fusion events (virus-cell
and cell-cell) may be principally responsible for the inhib-
ition of NDV infectivity by fucoidan from C. okamuranus.
Conclusion
Fucoidan inhibits NDV in vitro, and it did not exhibit
significant toxicity at effective concentrations. Fucoidan
exerted no direct inactivating effect on virions in a viru-
cidal assay. Our results support the concept that fucoi-
dan acts in early stages of viral infection so as to inhibit
viral-induced syncytia formation, probably by blocking
the F protein. It might be concluded that fucoidan repre-
sents a promising antiviral for the poultry industry that
may prevent NDV infection.
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Antiviral agents
Fucoidan was purchased as a dried powder from Kadoya
& Co., Kobe, Japan (lot A03012), extracted (as described
by Tako et al., 2000) from cultured kelp Cladosiphon
okamuranus harvested off the coast of Okinawa Island,
Japan. The polysaccharide preparation was certified to
contain 90.4% fucoidan (anthrone-sulfuric acid method)
and exhibit a mean molecular weight of 92.1 kDa (HPLC
method). The fucose and sulfate contents of fucoidan
were of 38.6 and 15.9%, respectively, with ash compris-
ing 19.6% of the content and other sugars comprising
23% (glucuronic acid and traces of xylose). Dried sam-
ples of fucoidan were suspended in Dulbecco’s modified
Eagle’s medium (DMEM) at a concentration of 2.5 mg/
mL and filtered through a membrane filter (pore size,
0.22 mm). Ribavirin (Vilonapediatrica, Valeant, México)
was used as an antiviral control.
Cell lines and viruses
Green African monkey kidney (Vero) cells and chicken
embryo fibroblasts were grown in DMEM/F-12 supple-
mented with 10% (v/v) fetal bovine serum and 1% (v/v)
antibiotics. The flasks were maintained in a humidified
atmosphere with 5% CO2 at 37°C. The La Sota and
wild-type lentogenic NDV strains were propagated in
9-day-old chicken embryo eggs. Stock viruses were har-
vested, titrated, and stored at −70°C until used. Both
strains were titered by hemadsorption and according to
their PFUs.
Cytotoxicity assay
The cytotoxicity of the compounds was evaluated by
MTT reduction assays. Vero cells were seeded in 96-
well plates at an initial density of 5 × 103 cells per well.
The cells were incubated with increasing concentrations
of the compounds for 48 h at 37°C and 5% CO2. MTT
solution (5 mg/mL) was added to the cells, which were
further incubated for 4 h. MTT was removed, and 100 μL
of DMSO were added for 5 min. The optical density
was measured at 570 nm (Microplate Autoreader EL311;
BIOTEK Instruments Inc. USA). Each experiment was
performed in sextuplicate, and experiments were repeated
at least three times. The cytotoxicity was expressed as the
CC50, which was the concentration of the test substances
that inhibited the growth of Vero cells by 50% compared
with the growth of the untreated cells.
Antiviral activity
The antiviral activity of fucoidan against NDV was
assessed using syncytia formation or plaque reduction
assays with monolayers of Vero cells grown in 24- or 6-
well plates. The assays were performed adding the com-
pounds during all infection cycles. Generally, 100 PFUsor 800 TCID50 of NDV were incubated with different
concentrations of drugs for 1 h at room temperature.
The virus was allowed to adsorb onto the cells for 1 h at
37°C. The residual inoculum was discarded, and cells
were washed three times with PBS, after which DMEM
(for syncytia assays) or medium containing 0.6% agar
and 0.001% trypsin (GIBCO; for PFU assays) was added
to the cells. Each concentration was investigated using
three culture wells per fucoidan concentration per ex-
periment, and the experiments were repeated three and
four times for the syncytia and plaque formation assays,
respectively; ribavirin was used as a control. Monolayers
were fixed with methanol:acetone after incubation for 48
or 72 h at 37°C in a 5% CO2 incubator and stained with
1% crystal violet, and subsequently, syncytia or plaques
were counted. By reference to the number of syncytia or
plaques observed in viral control monolayers (untreated
cultures), the IC50 was determined from dose–response
curves.
Virucidal assay
The virucidal activity of fucoidan against NDV was
assessed using plaque reduction assays with mono-
layers of Vero cells grown in 6-well plates. The assays
were performed by adding the compound (0, 10, or
100 μg/mL) to an equal volume to NDV (100 PFU/100 μL).
After 0, 1, 3, or 6 h, the mixtures were added to Vero
cells for 1 h at room temperature. Thereafter, the cells
were washed three times with PBS, and medium con-
taining 0.6% agar and 0.001% trypsin (PFU assays) was
added. Monolayers were fixed with methanol:acetone
after incubation for 72 h at 37°C and 5% CO2 and
stained with 1% crystal violet in an incubator, after
which plaques were counted.
Time of addition assay
Vero cell monolayers were infected with 800 TCID50 or
100 PFUs of NDV. Fucoidan was added at a concentra-
tion of 100 μg/mL at different times of infection: 60 min
preinfection, 0, 15, 30, 60, and 120 min postinfection
(Figure 4A), and 3, 5, and 7 h post-infection (data not
shown). Thereafter, for each treatment, cells were incu-
bated with fucoidan for 1 h and then washed three times
with PBS, and medium containing 0.6% agar and 0.001%
trypsin (PFU assays) was added. Monolayers were fixed
with methanol:acetone after incubation for 48 or 72 h at
37°C and 5% CO2 and stained with 1% crystal violet;
subsequently, plaques were counted.
Immunofluorescence
Vero cells grown on glass coverslips were treated with
100 μg/mL fucoidan at different times of infection
(60 min before infection and 0, 15, and 60 min postin-
fection) with 100 PFU/mL NDV. After 1 h at 37°C, the
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the monolayers were fixed with 1:1 methanol:acetone.
Thereafter, the cells were washed three more times with
PBS, incubated with blocking solution (PBS containing
1% BSA (w/v) for 30 min, and then incubated 2 h with
Newcastle monoclonal anti-HN antibody (dilution 1:100,
Chemicon International, CA). After washing three times
with PBS/Triton, the cells were incubated with bovine
antimouse IgG-FITC (dilution 1:100, Santa Cruz). After
washing three times with PBS/Triton, the slides were
mounted with Vectashield medium and visualized using a
confocal laser-scanning microscope (Olympus IX70, USA).
Viral penetration assay
Virus penetration into Vero cells was evaluated accord-
ing to the method reported by Huang and Wagner [29]
and modified by Highlander et al. [30]. Vero cell mono-
layers precooled at 4°C for 3 h were infected with 100
PFUs of NDV at 4°C for 1 h in the absence of fucoidan.
After washing three times with ice-cold PBS, different
concentrations of fucoidan were added to the mono-
layers, and the temperature was shifted to 37°C. After 30
min or 1 h of incubation at 37°C, the cells were treated
with 40 mM citrate buffer (pH 3.0) to inactivate unpene-
trated viruses. The cell monolayers were overlaid with
0.6% agar in DMEM and trypsin and subjected to PFU
assays.
Protein extraction and immunoblot assay
Total cell lysates were prepared from Vero cells infected
with NDV and treated with fucoidan at different times
of infection. Proteins were extracted with 1× lysis buffer
containing 10 mM Tris–HCl pH 7.5, 50 mM KCl, 2 mM
MgCl2, 1% Triton X-100, 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, and complete EDTA-free
protease inhibitors. After incubation on ice for 20 min,
the lysates were centrifuged at 13,000 × g for 10 min at
4°C.The amount of protein in the supernatant was mea-
sured by the Bradford assay (Bio-Rad). Equal amounts of
protein (40 μg) were separated by 10% SDS-PAGE and
transferred onto nitrocellulose membranes (Hybond-
ECL Amersham Biosciences). The membranes were
blocked with phosphate-buffered saline (PBS)/Triton
(0.1% Triton X-100 in PBS, pH 7.2) supplemented with
5% of BSA (w/v) for 1 h and then incubated overnight at
4°C with Newcastle monoclonal anti-HN antibody (dilu-
tion 1:500, Chemicon International CA) or mouse mono-
clonal anti-GAPDH antibody (dilution 1:500, Chemicon
International CA). After washing with PBS/Triton, the
membranes were incubated with HRP-Goat Anti-Mouse
IgG Conjugate (dilution 1:1000, Chemicon International,
CA, USA) for 2 h at room temperature. Peroxidase-
coupled antibodies were detected using an enhanced
chemiluminescence detection system (Roche).EMG. All authors read and approved the final manuscript.
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Fusion inhibition assay
Fusion inhibition assays were performed according to
the method reported by Zhu Jieqing [10]. Vero cell
monolayers in 24-well plates were infected with 800
TCID50 of the avirulent NDV strain (La Sota). After 12 h
of infection, the monolayers were washed three times
with PBS, digested by trypsin (GIBCO) in DMEM at
room temperature for 20 min, and then washed three
times with PBS, and the monolayers were incubated in
DMEM containing 5% fetal bovine serum for 12 h.
Monolayers were fixed with 1:1 methanol:acetone and
stained with 1% crystal violet. To detect its ability to in-
hibit fusion, fucoidan was added to the medium before
or after trypsin digestion.
Statistical analysis
The data were analyzed by SPSS 15 software. All vari-
ables were tested in triplicate for each experiment, and
experiments were repeated at least three times. The
CC50 and IC50 values were determined by probit regres-
sion analysis. One-way analysis of variance was per-
formed followed by Dunnett’s test. Values of *p<0.05
were considered statistically significant.
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